Trials / Completed
CompletedNCT01442090
Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy
A Phase II, Open-Label, Randomized Study of GDC-0980 Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following VEGF-Targeted Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 85 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study PIM4973g is a multicenter, international, open-label Phase II trial. Participants with metastatic renal cell carcinoma who have progressed on or after VEGF targeted therapy will be randomized in 1:1 to two groups either to receive daily GDC-0980 or everolimus orally.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus | Everolimus will be administered orally at a 10 mg daily dose. |
| DRUG | GDC-0980 | GDC-0980 will be administered orally at a 40 mg daily dose. |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2013-05-01
- Completion
- 2015-07-01
- First posted
- 2011-09-28
- Last updated
- 2016-08-10
Locations
22 sites across 5 countries: United States, France, Germany, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01442090. Inclusion in this directory is not an endorsement.